Proposed US Food and Drug Administration guidance for industry on distributing medical publications about the risks of prescription drugs and biological products: a misguided approach

JAMA Intern Med. 2014 Oct;174(10):1543-4. doi: 10.1001/jamainternmed.2014.4547.

Author

Sidney M Wolfe¹

Affiliation

¹ Public Citizen's Health Research Group, Washington, DC.

PMID: 25127222
DOI: 10.1001/jamainternmed.2014.4547

No abstract available

MeSH terms

Biological Products* / adverse effects
Drug Industry / standards*
Drug Industry / trends
Drug Labeling / standards*
Drug Labeling / trends
Humans
Information Dissemination* / methods
Practice Guidelines as Topic
Prescription Drugs* / adverse effects
Publications
Risk
United States
United States Food and Drug Administration

Substances

Biological Products
Prescription Drugs